Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Portfolio Pulse from
Protagonist Therapeutics will present final data from its Phase 2 REVIVE study on rusfertide for polycythemia vera at the 66th Annual ASH Meeting in December 2024.
November 05, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics is set to present final data from its Phase 2 REVIVE study on rusfertide at the ASH Meeting, which could influence investor sentiment and stock price.
The presentation of final Phase 2 study data at a major conference like ASH can significantly impact investor sentiment. Positive results could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100